1074 related articles for article (PubMed ID: 23152274)
21. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.
Joerger M; Huitema AD; Krähenbühl S; Schellens JH; Cerny T; Reni M; Zucca E; Cavalli F; Ferreri AJ
Br J Cancer; 2010 Feb; 102(4):673-7. PubMed ID: 20125159
[TBL] [Abstract][Full Text] [Related]
22. Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.
Kaji FA; Martinez-Calle N; Bishton MJ; Figueroa R; Adlington J; O'Donoghue M; Smith S; Byrne P; Paine S; Sovani V; Auer D; James E; Bessell EM; Grainge MJ; Fox CP
Br J Haematol; 2021 Nov; 195(4):561-570. PubMed ID: 34368948
[TBL] [Abstract][Full Text] [Related]
23. High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).
Salamoon M; Hussein T; Kenj M; Bachour M
Med Oncol; 2013 Dec; 30(4):690. PubMed ID: 23959450
[TBL] [Abstract][Full Text] [Related]
24. Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
Wendler J; Fox CP; Valk E; Steinheber C; Fricker H; Isbell LK; Neumaier S; Okosun J; Scherer F; Ihorst G; Cwynarski K; Schorb E; Illerhaus G
BMC Cancer; 2022 Sep; 22(1):971. PubMed ID: 36088292
[TBL] [Abstract][Full Text] [Related]
25. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
[TBL] [Abstract][Full Text] [Related]
26. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
[TBL] [Abstract][Full Text] [Related]
27. Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.
Wu J; Duan L; Zhang L; Sun Z; Fu X; Li X; Li L; Wang X; Zhang X; Li Z; Yu H; Chang Y; Nan F; Yan J; Tian L; Wang X; Zhang M
J Neurooncol; 2018 Nov; 140(2):427-434. PubMed ID: 30109672
[TBL] [Abstract][Full Text] [Related]
28. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F;
Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089
[TBL] [Abstract][Full Text] [Related]
29. A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.
Li Q; Ma Y; Lin Z; Ma J; Kang H; Zhang M; Xu H; Chen B
J Neurooncol; 2023 May; 163(1):39-46. PubMed ID: 35733032
[TBL] [Abstract][Full Text] [Related]
30. Continuous intrathecal injection therapy of methotrexate is a therapeutic option in primary CNS lymphoma.
Otani R; Yamada R; Kushihara Y; Inazuka M; Shinoura N
J Clin Neurosci; 2019 Nov; 69():26-30. PubMed ID: 31466902
[TBL] [Abstract][Full Text] [Related]
31. Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.
Ferreri AJ; Licata G; Foppoli M; Corazzelli G; Zucca E; Stelitano C; Zaja F; Fava S; Paolini R; Franzin A; Politi LS; Ponzoni M; Reni M
Oncologist; 2011; 16(3):336-41. PubMed ID: 21346023
[TBL] [Abstract][Full Text] [Related]
32. Anthracycline-containing regimens for treatment of follicular lymphoma in adults.
Itchaki G; Gafter-Gvili A; Lahav M; Vidal L; Raanani P; Shpilberg O; Paul M
Cochrane Database Syst Rev; 2013 Jul; (7):CD008909. PubMed ID: 23832787
[TBL] [Abstract][Full Text] [Related]
33. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Qian L; Zhou C; Shen J; Cen J; Yin W
Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.
Makino K; Nakamura H; Hide T; Kuroda J; Yano S; Kuratsu J
Int J Clin Oncol; 2015 Feb; 20(1):29-34. PubMed ID: 24722885
[TBL] [Abstract][Full Text] [Related]
35. Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma.
Farhi J; Laribi K; Orvain C; Hamel JF; Mercier M; Sutra Del Galy A; Clavert A; Rousselet MC; Tanguy-Schmidt A; Hunault-Berger M; Moles-Moreau MP
Ann Hematol; 2018 Dec; 97(12):2391-2401. PubMed ID: 30091022
[TBL] [Abstract][Full Text] [Related]
36. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Olivier G; Clavert A; Lacotte-Thierry L; Gardembas M; Escoffre-Barbe M; Brion A; Cumin I; Legouffe E; Solal-Celigny P; Chabin M; Ingrand P; Colombat P; Delwail V
Am J Hematol; 2014 Nov; 89(11):1024-9. PubMed ID: 25052698
[TBL] [Abstract][Full Text] [Related]
37. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma.
Kobayashi H; Yamaguchi S; Motegi H; Kaneko S; Endou S; Onimaru R; Terasaka S; Houkin K
J Chemother; 2019 Feb; 31(1):35-41. PubMed ID: 30773132
[TBL] [Abstract][Full Text] [Related]
39. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
Bokstein F; Lossos A; Lossos IS; Siegal T
Leuk Lymphoma; 2002 Mar; 43(3):587-93. PubMed ID: 12002763
[TBL] [Abstract][Full Text] [Related]
40. Continued-Maintenance Therapy with High-dose Methotrexate Improves Overall Survival of Patients with Primary Central Nervous System Lymphoma.
Nakajima K; Mizobuchi Y; Fujihara T; Azumi M; Takagi Y
J Med Invest; 2021; 68(3.4):286-291. PubMed ID: 34759146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
